美好發展(02662.HK):截至1月底止7個月純利為1.72億港元
格隆匯 3 月 22日丨美好發展(02662.HK)公佈,截至2021年1月31日止止七個月,公司收益為2106萬港元,毛利為388.7萬港元,公司擁有人應占期內溢利為1.72億港元,每股盈利為0.16港元。
期內,集團業務整體營收情況相較於截至2021年131日七個月財務指標錄得大幅回升,期內共錄得收益約2110萬港元,同比上升178%,錄得毛利390萬港元,同比上升55%。期內溢利約170.0百萬港元,每股基本盈利為0.16港元。
集團於期內錄得溢利主要因為集團於2021年1月15日完成了出售事項及於2020年9月26日完成了註銷事項,產生一次性的處置╱註銷附屬公司收入合計約1.80億港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.